Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chinook Therapeutics, Inc. (formerly Aduro)
With
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ECOG ≤ 1
Willing to undergo tumor biopsies from injected and distal lesions
Must have two biopsy accessible lesions:
* \* one lesion must be ≥10 mm and \<100 mm in longest diameter, accessible for repeated intratumoral (IT) injection and accessible for baseline and on-treatment biopsies.
* a second (distal) lesion must be accessible for baseline and on-treatment biopsy and must be distinct from the injected lesion.
* tumors encasing major vascular structures (i.e., carotid artery or tumors close to other vital organs), are not considered appropriate
You may not be if
Patients who require local palliative measures such as XRT or surgery
Symptomatic or untreated leptomeningeal disease.
Presence of symptomatic central nervous system (CNS) metastases
Impaired cardiac function or clinically significant cardiac disease
Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.
Active infection requiring systemic antibiotic therapy.
Known history of Human Immunodeficiency Virus (HIV) infection.
Active Epstein-Barr virus (EBV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Malignant disease, other than that being treated in this study.
Clareo Health | Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
